SPRYD7 and colorectal carcinoma: Here, SPRYD7 was overexpressed in KM12C, KM12SM, SW480, and SW620 CRC cell lines with different metastatic abilities, and the tumorigenic and metastatic changes induced by its stable overexpression have been investigated via in vitro assays to analyze its role in CRC progression and metastasis.